Combination Immunotherapy in Rare Cancers Under InvesTigation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Using ctDNA to Determine Therapies for Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ARID1A and/or KDM6A Mutation and CXCL13 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- Status
- COMPLETED
- Phase
- N/A
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
- Status
- RECRUITING
- Phase
- PHASE2
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
- Status
- COMPLETED
- Phase
- PHASE1